No Detail Found!

Comparison of effect of sodium-glucose co-transporter-2 (SFLT-2) inhibitors with dipeptidyl peptidase-4 (DPP-4) inhibitors on hba1c level in type 2 diabetes in pakistani population

Author(s)
Muhammad Amir Misbah Ul Qamar Combined Military Hospital Sialkot/National University of Medical Sciences (NUMS) Pakistan
Tahira Sumreen Nishtar Hospital, Multan Pakistan
Andaleeb Khan Combined Military Hospital Multan/National University of Medical Sciences (NUMS) Pakistan
Kamil Rehman Butt Combined Military Hospital Lahore/National University of Medical Sciences (NUMS) Pakistan,
Ejaz Ali Combined Military Hospital Sialkot/National University of Medical Sciences (NUMS) Pakistan,
Ayesha Rehman Armed Forces Institute of Cardiology/National Institute of Heart Diseases/National University of Medical Sciences (NUMS) Rawalpindi Pakistan
Abstract
Objective: To compare the effect of SGLT-2 inhibitors with DPP-4 inhibitors as the add on therapy to Metformin on HBA1c level in type 2 diabetes patients in Pakistani population. Study Design: Quasi-experimental study. Place and Duration of Study: Combined Military Hospital Sialkot, Pakistan from Nov to Apr 2020. Methodology: The study population comprised of 300 type-II diabetes patients with poorly controlled diabetes on Metformin managed at Combined Military Hospital Sialkot, Pakistan. Patients were divided into two groups via lottery method. GroupA received the SGLT-2 inhibitors at standard dose while group-B received the DPP-4 inhibitors at the usual standard does as recommended by the consultant medical specialist. Values of glycosylated hemoglobin were compared three months after the start of study. Results: Mean age of the patients was 44.31 ± 5.841 years. Mean duration of type 2 diabetes mellitus in the study participants was 4.18 ± 6.369 years. HBA1c after three months of treatment in the SGLT-2 inhibitors-group was 7.01 ± 0.14 mmol/L while in the DPP-4 inhibitors-group was 7.89 ± 0.99 mmol/L. Difference between the two groups was statistically significant (pvalue <0.01). The result showed SGLT-2 inhibitors as the better option for add on therapy to Metformin as compared to DPP-4 inhibitors. Conclusion: SGLT-2 inhibitors emerged as better option to lower the HBA1c level as compared to DPP-4 inhibitors as the add on therapy to Metformin as there was statistically significant difference in HBA1c levels after three months of therapy in both the groups.
Publication Details
Page(s) 25-28
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 72, Issue: 1, Year: 2022

Request the full text from PASTIC

Keywords
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Typ-2 diabetes mellitus.
0

Citations

0

Downloads

89

Views